CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xanthus Pharmaceuticals, Inc., today announced that a paper published in the journal Leukemia Research reported on the results of an in vitro study conducted by Xanthus in multi-drug resistant (MDR) leukemia cell lines. In the study the cytotoxic effect of Xanafide® (amonafide malate), was found to be unaffected by the over-expression of P-glycoprotein (Pgp+) in acute myeloid leukemia (AML) cell lines and that Xanafide was neither a substrate nor an inhibitor of Pgp. Increased levels of Pgp+ expression are a common cause of multi-drug resistance (MDR) for all of the currently used topoisomerase II inhibitors used for the treatment of AML. The company believes that this finding supports the positive levels of complete remissions observed with Xanafide in Phase 1 and Phase 2 trials in AML.
